Not checked for notices yet.
CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy
Urszula M. Domanska, Hetty Timmer-Bosscha, Wouter B. Nagengast and 8 more (opens in a new tab)
Neoplasia: An International Journal for Oncology Research · 2012
doi:10.1593/neo.12324 (opens in a new tab)
Cited by papers we hold 4
- Targeting cytokine and chemokine signaling pathways for cancer therapy · 2024No notice
- Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges · 2022No notice
- Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer · 2022No notice
- CD4 + T cells contribute to neurodegeneration in Lewy body dementia · 2021No notice
Questions about this paper
We email you if it is retracted, withdrawn, corrected or flagged.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.